AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Track Group, Inc.
Video analysis: TRCK
All videosNo video analysis for this stock yet. Request one from our team.
News: TRCK
High Roller Technologies Launches Beta Version of ROLR™ Prediction Markets Platform; Commercial Launch on Track for October 2026
LAS VEGAS, Nevada, Sept. 15, 2026 (GLOBE NEWSWIRE) -- High Roller Technologies, Inc. ("High Roller" or the "Company") (NYSE: ROLR), a publicly traded online gaming and prediction markets company, today launched the closed beta of its ROLR™ prediction markets platform with a select group of invited participants. As announced on September 2, 2026, the invitation-only beta represents the Company's final controlled testing and optimization phase ahead of its commercial launch targeted for late October 2026.
Exxon's 2030 Targets Call for $35 Billion More in Cash Flow. Here's the Milestone That Tells You It's on Track By 2028.
ExxonMobil is a giant, integrated energy company. Although Exxon is making capital investments worldwide, one market is especially important to its 2030 target.
5 Stocks to Buy as U.S. Manufacturing Stays on Growth Track
U.S. manufacturing stays on track, with lean inventories and solid production supporting Caterpillar, Kubota, Nordson and two other industrial stocks.
Kodiak AI On Track For Year-End Driverless Long-Haul Launch as Safety Case Readiness Reaches 93%
MOUNTAIN VIEW, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kodiak AI, Inc. (“Kodiak”) (Nasdaq: KDK), a leading provider of Physical AI-powered autonomous driving technology, today reaffirmed that it remains on track to launch driverless long-haul commercial service by the end of 2026. The company's Autonomy Readiness Measure ("ARM") for long-haul driverless operations reached 93% at the end of August 2026, up from 91% at the end of July.
Peruvian Metals on Track for Full Production for 2026 at the Aguila Norte Processing Plant and Reports Positive Sample Results from the Tailings Area
Edmonton, Alberta--(Newsfile Corp. - September 8, 2026) - Peruvian Metals Corp. (TSXV: PER) (OTC PINK: DUVNF) ("Peruvian Metals" or the "Company") announces the completion of a major overall and maintenance program and the year-to-date production results for 2026 at its 80-per-cent-owned Aguila Norte processing plant ("Aguila Norte" or the "Plant") located in Northern Peru. During the months of July and August, the Plant processed a total of 6,046 metric tonnes (mt).
Bill Ackman Says Pershing Square Has Achieved a 20% Gross Annual Return Since Inception and Aims to Keep Beating That Bar. Can His Newly Launched Funds Live Up to the Track Record?
Bill Ackman's Pershing Square hedge fund has averaged a 20% annual return since 2004. His Pershing Square portfolio is highly concentrated.
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Fast Track designation underscores the significant unmet need for patients with systemic sclerosis-associated Raynaud's phenomenon (SSc-RP), a debilitating manifestation affecting up to 90% of SSc patients No therapy is currently approved in the U.S. to treat SSc-RP and management options are limited and often inadequate for patients with more severe disease Liquidia plans to initiate RE-WARM, a Phase 2a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026 MORRISVILLE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP).
C3.ai Reports Strong Q1: Turnaround is On Track, CEO Says
C3.ai (NYSE:AI) posted its fiscal 2027 first-quarter results after Wednesday's closing bell, beating estimates on the top and bottom lines. Here's a look at the details inside the report.
